BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) CEO Jon P. Stonehouse sold 184,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Tuesday, January 11th. The shares were sold at an average price of $15.04, for a total value of $2,767,360.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
NASDAQ:BCRX opened at $15.48 on Friday. The firm’s fifty day moving average is $12.87 and its two-hundred day moving average is $14.51. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of -12.19 and a beta of 2.49. BioCryst Pharmaceuticals, Inc. has a one year low of $8.37 and a one year high of $18.48.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Tuesday, November 2nd. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The company had revenue of $40.99 million during the quarter, compared to analysts’ expectations of $37.75 million. During the same quarter last year, the business posted ($0.26) earnings per share. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -1.26 EPS for the current year.
Several brokerages have issued reports on BCRX. Oppenheimer initiated coverage on shares of BioCryst Pharmaceuticals in a report on Thursday, December 9th. They issued an “outperform” rating and a $16.00 target price for the company. Zacks Investment Research upgraded BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Royal Bank of Canada cut their target price on BioCryst Pharmaceuticals from $16.00 to $14.00 and set a “sector perform” rating for the company in a research report on Thursday, November 4th. Finally, Barclays reduced their price target on shares of BioCryst Pharmaceuticals from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, November 4th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $19.82.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever.
Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.